| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $261.6M | — | +6.1% |
| R&D Expense | $43.3M | — | +16.2% |
| SG&A Expense | $36.0M | — | +20.4% |
| Operating Income | $30.0M | — | +2.4% |
| Pre-tax Income | $29.2M | — | +5.2% |
| Income Tax | $9.6M | — | +34.1% |
| Net Income | $19.6M | — | -4.9% |
| EPS (Basic) | $0.06 | — | +0.0% |
| EPS (Diluted) | $0.06 | — | +20.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $339.4M | -18.3% | -35.3% |
| Accounts Receivable | $12.6M | +21.3% | +34.7% |
| Current Assets | $7.72B | -4.8% | +15.1% |
| Total Assets | $8.60B | -4.0% | +13.9% |
| Current Liabilities | $7.76B | -4.0% | +15.3% |
| Total Liabilities | $7.94B |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $51.8M | — | -3.5% |
| Capital Expenditures | $10.1M | — | +114.7% |
| Investing Cash Flow | -$60.9M | — | -26.9% |
| Financing Cash Flow | -$385.7M | — | +4.2% |
| Free Cash Flow | $41.7M | — | -14.9% |
| +16.8% |
| Stockholders' Equity | $659.1M | -6.4% | -12.2% |